(Q33990959)

English

Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

30 July 2017

Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study (English)

1 reference

Europe PubMed Central

30 July 2017

1 reference

based on heuristic

inferred from title

Brainstem glioma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Henry Seth Friedman

7

object named as

Henry S Friedman

1 reference

Europe PubMed Central

30 July 2017

Sridharan Gururangan

1

object named as

Sridharan Gururangan

1 reference

Europe PubMed Central

30 July 2017

author name string

Susan N Chi

2

1 reference

Europe PubMed Central

30 July 2017

Tina Young Poussaint

3

1 reference

Europe PubMed Central

30 July 2017

Arzu Onar-Thomas

4

1 reference

Europe PubMed Central

30 July 2017

Richard J Gilbertson

5

1 reference

Europe PubMed Central

30 July 2017

Sridhar Vajapeyam

6

1 reference

Europe PubMed Central

30 July 2017

Roger J Packer

8

1 reference

Europe PubMed Central

30 July 2017

Brian N Rood

9

1 reference

Europe PubMed Central

30 July 2017

James M Boyett

10

1 reference

Europe PubMed Central

30 July 2017

Larry E Kun

11

1 reference

Europe PubMed Central

30 July 2017

language of work or name

0 references

publication date

17 May 2010

1 reference

Europe PubMed Central

30 July 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

30 July 2017

28

1 reference

Europe PubMed Central

30 July 2017

18

1 reference

Europe PubMed Central

30 July 2017

3069-3075

1 reference

Europe PubMed Central

30 July 2017

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2903337

5 July 2018

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2903337

5 July 2018

Pathways mediating resistance to vascular endothelial growth factor-targeted therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2903337

5 July 2018

Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: outcome compared with conventional chemotherapy: a report from the Children's Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2903337

5 July 2018

What is the risk of intracranial bleeding during anti-VEGF therapy?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2903337

5 July 2018

Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2903337

5 July 2018

Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2903337

5 July 2018

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2903337

5 July 2018

A perivascular niche for brain tumor stem cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2903337

5 July 2018

Intratumoral hemorrhage among children with newly diagnosed, diffuse brainstem glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2903337

5 July 2018

Managing patients treated with bevacizumab combination therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2903337

5 July 2018

Only a specific subset of human peripheral-blood monocytes has endothelial-like functional capacity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2903337

5 July 2018

Imaging angiogenesis: applications and potential for drug development

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2903337

5 July 2018

Overview of bevacizumab: a new cancer therapeutic strategy targeting vascular endothelial growth factor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2903337

5 July 2018

Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2903337

5 July 2018

Monitoring cytotoxic tumour treatment response by diffusion magnetic resonance imaging and proton spectroscopy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2903337

5 July 2018

Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2903337

5 July 2018

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2903337

5 July 2018

Topotecan for the treatment of recurrent or progressive central nervous system tumors - a pediatric oncology group phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2903337

5 July 2018

Tumor angiogenesis: therapeutic implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2903337

5 July 2018

What Is the Evidence That Tumors Are Angiogenesis Dependent?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2903337

5 July 2018

Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2903337

29 October 2018

Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2903337

29 October 2018

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2903337

29 October 2018

Bevacizumab, bleeding, thrombosis, and warfarin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2903337

29 October 2018

Immunohistochemical markers for prognosis of oligodendroglial neoplasms.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2903337

29 October 2018

Angiogenic profile of childhood primitive neuroectodermal brain tumours/medulloblastomas.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2903337

29 October 2018

Irinotecan therapy in adults with recurrent or progressive malignant glioma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2903337

29 October 2018

A phase II evaluation of thiotepa in pediatric central nervous system malignancies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2903337

29 October 2018

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2903337

29 October 2018

Expression of VEGF and its receptors in different brain tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/20479404

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2009.26.8789

1 reference

Europe PubMed Central

30 July 2017

1 reference

Europe PubMed Central

30 July 2017

1 reference

Europe PubMed Central

30 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33990959&oldid=1953222738"